Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?
Patients with chronic kidney disease (CKD) have an elevated prevalence of atheromatous (ATH) and/or non-atheromatous (non-ATH) cardiovascular disease (CVD) due to an array of CKD-related risk factors, such as uremic toxins (UTs). Indeed, UTs have a major role in the emergence of a spectrum of CVDs,...
Main Authors: | Carolla El Chamieh, Sophie Liabeuf, Ziad Massy |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Toxins |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6651/14/4/280 |
Similar Items
-
Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation
by: Sophie Liabeuf, et al.
Published: (2018-06-01) -
Uremic Toxins and Vascular Dysfunction
by: Isabelle Six, et al.
Published: (2020-06-01) -
Characteristics of atheromatosis in the prediabetes stage: a cross-sectional investigation of the ILERVAS project
by: Enric Sánchez, et al.
Published: (2019-11-01) -
Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins
by: Solène M. Laville, et al.
Published: (2021-01-01) -
Protein-Bound Uremic Toxins: New Insight from Clinical Studies
by: Ziad A. Massy, et al.
Published: (2011-07-01)